Can Apigenin Be an Effective Therapeutic Agent Against Experimental Renal Ischemia-Reperfusion Injury?

Authors : Ömer Topdağı, Mustafa Can Güler, Ersen Eraslan, Fazile Nur Ekinci Akdemir, Ayhan Tanyeli, Saime Özbek Şebin, Engin Şebin

Pages : 53-56

Doi:10.21765/pprjournal.1487201

View : 18 | Download : 29

Publication Date : 2024-07-31

Article Type : Research Paper

Abstract :Aim: This study aims to reveal the effects of two doses of apigenin (API) against renal ischemia-reperfusion injury (R I/R). Material and Methods: For this purpose, 5 and 10 mg/kg doses of API were preferred in our study, and the groups were designed as sham, R I/R, 5 mg/kg API, and 10 mg/kg API groups for the implementation of the experimental protocol. In the R I/R model, 1-hour ischemia and 24-hour reperfusion periods were preferred. Oxidative and inflammatory markers were measured biochemically in samples taken at the end of the experiment. Results: Biochemical results showed that oxidative and inflammatory markers increased significantly in the R I/R group, but antioxidant activities decreased significantly. In the 5 and 10 mg/kg API groups, R I/R damage was alleviated considerably, with these markers approaching the sham group values. Conclusion: As a result, the study\'s results determined that two different doses of API were effective against R I/R-induced kidney damage.
Keywords : Apigenin, böbrek, iskemi reperfüzyon